EGFR and neoplasm: It can inhibit receptor tyrosine kinases (RTKs), such as VEGFR-2, VEGFR-3, epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 3 (ErbB3) that are essential for angiogenesis and tumour proliferation.